Please try another search
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.
Name | Age | Since | Title |
---|---|---|---|
Wee Kiat Tan | 36 | 2019 | CEO, COO & Director |
Keng Kiat Toh | 82 | 2023 | Independent Director |
Ahmad Radzi Bin Ahmad Badruddin | 65 | 2023 | Member of Scientific Advisory Board |
Chak Hua Yew | 42 | 2023 | Independent Director |
Shu Wang | 67 | 2023 | Member of Scientific Advisory Board |
Yuin Han Loh | 46 | 2023 | Independent Director |
Harry Zemon | 57 | 2023 | Member of Scientific Advisory Board |
Kei Wei Leong | 48 | 2023 | Independent Director |
Heng Phon Too | 64 | 2023 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review